Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("Rivaroxaban")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 178

  • Page / 8
Export

Selection :

  • and

Resolution of giant left atrial appendage thrombus with rivaroxabanHAMMERSTINGL, Christoph; PÖTZSCH, Berndt; NICKENIG, Georg et al.Thrombosis and haemostasis. 2013, Vol 109, Num 4, pp 583-584, issn 0340-6245, 2 p.Article

Optimisation of the assa\ys for the measurement of clotting factor activity in the presence of rivaroxabanGEROTZIAFAS, Grigoris T; BACCOUCHE, Hela; SASSI, Mouna et al.Thrombosis research. 2012, Vol 129, Num 1, pp 101-103, issn 0049-3848, 3 p.Article

Assays for Measuring Rivaroxaban: Their Suitability and LimitationsLINDHOFF-LAST, Edelgard; SAMAMA, Meyer Michel; ORTEL, Thomas L et al.Therapeutic drug monitoring. 2010, Vol 32, Num 6, pp 673-679, issn 0163-4356, 7 p.Article

Rivaroxaban: un anti-thrombotique original : FA, CA, anti-thrombotiques: les grandes communications: SYMPOSIUMS DES LABORATOIRES BAYER HEALTHCARE PHARMACEUTICALKEVORKIAN, J.-P; CALLIF, R; ALEXANDER, J et al.Archives des maladies du coeur et des vaisseaux. Pratique. 2012, Num FEV, pp 13-15, issn 1261-694X, 3 p., HS1Article

The effect of food on the absorption and pharmacokinetics of rivaroxabanSTAMPFUSS, Jan; KUBITZA, Dagmar; BECKA, Michael et al.International journal of clinical pharmacology and therapeutics. 2013, Vol 51, Num 7, pp 549-561, issn 0946-1965, 13 p.Article

Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratoriesASMIS, L. M; ALBERIO, L; ANGELILLO-SCHERRER, A et al.Thrombosis research. 2012, Vol 129, Num 4, pp 492-498, issn 0049-3848, 7 p.Article

Anticoagulant drugs: what is new?KEI, A; FLORENTIN, M; ELISAF, M. S et al.International angiology. 2011, Vol 30, Num 4, pp 299-320, issn 0392-9590, 22 p.Article

Clinical Pharmacokinetic and Pharmacodynamic Profile of RivaroxabanMUECK, Wolfgang; STAMPFUSS, Jan; KUBITZA, Dagmar et al.Clinical pharmacokinetics. 2014, Vol 53, Num 1, pp 1-16, issn 0312-5963, 16 p.Article

ROCKET-AF: données avec le rivaroxaban chez les patients avec altération modérée de la fonction rénale : Congrès de l'ESC 2011: Acutalités cardiologiquesFOX, K. A. A; KEVORKIAN, J.-P.Archives des maladies du coeur et des vaisseaux. Pratique. 2012, Num FEV, pp 9-10, issn 1261-694X, 2 p., HS1Article

Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxabanDOUXFILS, Jonathan; TAMIGNIAU, Anne; CHATELAIN, Bernard et al.Thrombosis and haemostasis. 2013, Vol 110, Num 4, pp 723-731, issn 0340-6245, 9 p.Article

Questions ― réponses sur l'utilisation du rivaroxaban pour le traitement de la maladie thromboembolique veineuse = Questions ― answers on the use of rivaroxaban for the treatment of venous thromboembolic diseasePERNOD, G; ELIAS, A; GOUIN, I et al.Journal des maladies vasculaires. 2012, Vol 37, Num 6, pp 300-310, issn 0398-0499, 11 p.Article

Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration timeMANI, Helen; HESSE, Christian; STRATMANN, Gertrud et al.Thrombosis and haemostasis. 2011, Vol 106, Num 1, pp 156-164, issn 0340-6245, 9 p.Article

The mechanism of action of rivaroxaban ― an oral, direct Factor Xa inhibitor ― compared with other anticoagulantsMICHEL SAMAMA, Meyer.Thrombosis research. 2011, Vol 127, Num 6, pp 497-504, issn 0049-3848, 8 p.Article

New anticoagulants: how to deal with treatment failure and bleeding complicationsKAZMI, Rashid S; LWALEED, Bashir A.British journal of clinical pharmacology. 2011, Vol 72, Num 4, pp 593-603, issn 0306-5251, 11 p.Article

An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasmaSAMAMA, Meyer Michel; AMIRAL, Jean; GUINET, Céline et al.Thrombosis and haemostasis. 2010, Vol 104, Num 5, pp 1078-1079, issn 0340-6245, 2 p.Article

Drug Interactions with Rivaroxaban Following Total Joint Replacement SurgeryKWONG, Louis M; TONG, Lisa M.The Annals of pharmacotherapy. 2012, Vol 46, Num 9, pp 1232-1238, issn 1060-0280, 7 p.Article

Démarche qualité autour d'un nouvel anticoagulant en prise orale en chirurgie prothétique: le rivaroxaban XARELTO® = Quality approach for a new oral anticoagulant in prosthetic surgery: XARELTO® (rivaroxaban)HOFFMANN, C; ROYNETTE, F; FALZONE, E et al.Risques & qualité en milieu de soins. 2011, Num 4, pp 266-271, issn 1767-3445, 6 p.Article

Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit ModelGODIER, Anne; MICLOT, Anastasia; LE BONNIEC, Bernard et al.Anesthesiology (Philadelphia). 2012, Vol 116, Num 1, pp 94-102, issn 0003-3022, 9 p.Article

Rivaroxaban and false positive lupus anticoagulant testingMERRIMAN, Eileen; KAPLAN, Zane; BUTLER, Jenny et al.Thrombosis and haemostasis. 2011, Vol 105, Num 2, pp 385-386, issn 0340-6245, 2 p.Article

Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxabanHERRMANN, Richard; THOM, James; WOOD, Alicia et al.Thrombosis and haemostasis. 2014, Vol 111, Num 5, pp 989-995, issn 0340-6245, 7 p.Article

Use of rivaroxaban in Germany: a database drug utilization study of a drug started in hospitalJOBSKI, Kathrin; ENDERS, Dirk; AMANN, Ute et al.European journal of clinical pharmacology. 2014, Vol 70, Num 8, pp 975-981, issn 0031-6970, 7 p.Article

A case report describing a suspected rivaroxaban hypersensitivity reaction in a surgical patientYATES, J; CHOUDHRY, M; KEYS, G et al.Journal of clinical pharmacy and therapeutics (Print). 2013, Vol 38, Num 2, pp 159-161, issn 0269-4727, 3 p.Article

A NEW ERA OF ANTICOAGULATIONHAINAUT, P. H.Acta clinica belgica (English ed.). 2012, Vol 67, Num 6, pp 394-398, issn 1784-3286, 5 p.Article

Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controlsSAMAMA, Meyer Michel; CONTANT, Genevieve; SPIRO, Theodore E et al.Thrombosis and haemostasis. 2012, Vol 107, Num 2, pp 379-387, issn 0340-6245, 9 p.Article

Management consensus guidance for the use of rivaroxaban ― an oral, direct factor Xa inhibitorTURPIE, Alexander G. G; KREUTZ, Reinhold; LAU, Juan L et al.Thrombosis and haemostasis. 2012, Vol 108, Num 5, issn 0340-6245, 876-892 [11 p.]Article

  • Page / 8